MIRA INFORM REPORT

 

 

Report Date :

14.01.2014

 

IDENTIFICATION DETAILS

 

Name :

NOVARTIS PHARMA (PAKISTAN) LIMITED

 

 

Registered Office :

15, West Wharf Road, Karachi - 74000,

 

 

Country :

Pakistan

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

1963

 

 

Com. Reg. No.:

0001679

 

 

Legal Form :

Public Unlisted Company

 

 

Line of Business :

Importers, Manufacturers and distributors of Pharmaceutical Products.

 

 

No. of Employees :

570

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

Slow but correct

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2013

 

Country Name

Previous Rating

(30.06.2013)

Current Rating

(30.09.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors

 

Source : CIA

 

 

 

 

company name and address

           

NOVARTIS PHARMA (PAKISTAN) LIMITED

 

 

Full Address       

 

Registered Address & Factory

15, West Wharf Road, Karachi - 74000, Pakistan.

                       

Tel #

92 (21) 32313386 - 90, 32202071 - 80

Fax #

92 (21) 32311009, 32310027

 

 

Short Description Of Business

 

a.

Nature of Business        

Importers, Manufacturers and distributors of Pharmaceutical Products.

b.

Year Established

1963

c.

Registration #

0001679

 

 

Branches

 

 In Islamabad, Lahore, Peshawar & Multan              

 

 

Auditors

           

A.F. Ferguson & Co.

(Chartered Accountants)

State Life Building 1-C, Off I.I. Chundrigar Road, Karachi-74000, Pakistan.

 

 

Legal Status

           

Novartis Pharma (Pakistan) Limited is a public unlisted company incorporated in Pakistan.

 

6.

Authorized Capital 

Rs. 3,875,000,000/- divided into 387,500,000 shares of 10/- each

 

Issued & Paid up Capital

Rs. 3,860,408,000/- divided into 386,040,800 shares of Rs. 10/- each

 

Details of Directors

 

Names

Designation

Mr. Shahab Rizvi

 

Mr. Christopher Snook

 

Mr. Merajuddin

 

Mr. Rainer Boehm

 

Mr. Badruddin Vellani

 

Mr. Francesco Balestrieri

 

Mr. Syed Khalid Noor

Chief Executive

 

Director

 

Director

 

Director

 

Director

 

Director

 

Director

 

 

Categories of Shareholders                 

 

Categories

Shareholding (%)

Individuals

 

Modarabas

 

Joint Stock Companies

 

Financial Institution

0.02

 

0.00

 

99.98

 

0.09

 

 

Parent Company

 

Novartis AG, a company organized and existing under the laws of Switzerland, is the Company’s parent company.

 

 

Business Activities

 

Subject Company is engaged in the import, manufacture, sale and distribution of pharmaceutical products.

 

 

Number of Employees

 

570

 

 

Actual Capacity & Production

 

 The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Years

In Pak Rupees

2011

2012

8,708,796,000/-

9,761,458,000/-

 

 

Customers

 

Mainly exist in all over Pakistan

 

 

Bankers

 

MCB Bank Limited, Pakistan.

Faysal Bank Limited, Pakistan.

Habib Metropolitan Bank Limited, Pakistan.

Habib Bank Limited, Pakistan.

Silk Bank Limited, Pakistan.

Soneri Bank Limited, Pakistan.

           

 

Future Prospects

 

The future is likely to remain challenging, given the continued devaluation of the rupee and the corresponding increase in operating costs. It is hopeful  that the drug regulatory authority of Pakistan will soon agree to an inflationary price adjustment mechanism. The Company will continue to use all possible means to appeal and make representations to the drug regulatory authority of Pakistan and other healthcare stakeholders. We are continuing to upgrade our manufacturing facilities at Jamshoro, in terms of quality & capacity as means towards improving operational efficiencies in Pakistan.

 

 

Memberships

 

KCCI

PPMA

FPCCI

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 106.40

UK Pound

1

           Rs. 175.50

Euro

1

           Rs. 145.00

 

 

Comments

 

Subject Company is well known and directors are resourceful and experienced businessmen. Trade relations are reported as fair.  Payments to creditors etc are reported as normal. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

           

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.61.52

UK Pound

1

Rs.101.48

Euro

1

Rs.84.11

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIS

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.